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Background – Obesity is a risk factor for arterial and venous thromboembolism. 
However, it is not known whether obesity mediates risk through shared mechanisms. 
In a population-based cohort, we aimed to compare the impact of obesity measures 
on risk of venous thromboembolism (VTE) and myocardial infarction (MI), and 
explore how obesity-related atherosclerotic risk factors influenced these 
relationships.  
 
Methods – Measures of body composition including body mass index (BMI), waist 
circumference (WC), hip circumference (HC), waist-hip ratio (WHR) and waist-to-
height ratio (WHtR) were registered in 6708 subjects aged 25-84 years, who 
participated in the Tromsø Study (1994-1995). Incident VTE- and MI-events were 
registered until January 1, 2011.  
 
Results – There were 288 VTEs and 925 MIs during a median of 15.7 years of 
follow-up. All obesity measures were related to risk of VTE. In linear models, WC 
showed the highest risk estimates in both genders. In categorized models (highest 
versus lowest quintile), WC showed highest risk in men (HR 3.59; 95%CI: 1.82-7.06) 
and HC in women (HR 2.27; 95%CI: 1.54-4.92). Contrary, WHR and WHtR yielded 
the highest risk estimates for MI. The HR of MI (highest vs. lowest quintile) for WHR 
was 2.11 (95%CI: 1.59-2.81) in men and 1.62 (95%CI: 1.13-2.31) in women. The risk 
estimates for MI were substantially attenuated after adjustment for atherosclerotic 
risk factors, whereas the estimates for VTE remained unchanged.  
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Conclusions – Our findings suggest that the impact of body fat distribution, and the 













Several studies have shown an association between arterial (e.g. myocardial 
infarction and stroke) and venous (deep vein thrombosis and pulmonary embolism) 
thromboembolism during the last decade (1-4). It has been suggested that this link 
may be caused by shared risk factors (5). Obesity has been consistently associated 
with both arterial and venous thromboembolism (6-11). Epidemiological studies have 
reported a 1.5-2 fold increased risk of myocardial infarction (MI) (12, 13) and a 2-3 
fold increased risk of venous thromboembolism (VTE) (9, 14-17) in obese subjects. 
However, it is not known whether obesity contributes to the risk of arterial and 
venous thrombosis through the same pathophysiological mechanism(s).  
Obesity is a quite heterogeneous condition, and body fat distribution may have 
differential impact on the risk of diseases (18). Anthropometric measures such as 
waist circumference (WC), waist to hip ratio (WHR) and waist to height ratio (WHtR) 
have been shown to predict risk of arterial cardiovascular disease more accurately 
than body mass index (BMI) (19, 20). Visceral obesity appears to be essential for 
development of the metabolic syndrome, and is closely related to atherosclerotic risk 
factors such as hypertension, dyslipidaemia and hyperglycaemia (18, 21). Targeted 
interventions to reduce atherosclerotic risk factors lowers the risk of arterial 
thrombosis (22), further supporting the concept that arterial thrombosis in obese 
subjects to a large extent is mediated by a concurrent rise in atherosclerotic risk 
factors. 
We have previously shown that all measures of obesity are associated with 
risk of VTE (23), and reported that WC yielded the highest risk estimates, and 
identified most subjects at increased risk (23). The mechanism by which obesity 
increases the risk of VTE is unclear, and the impact of co-existing atherosclerotic risk 
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factors on this relationship has not been well studied. If atherosclerotic risk factors 
modify the association between obesity measures and risk of VTE, targeted 
interventions to reduce atherosclerotic risk factors may potentially prevent obesity-
related VTE.  
In the present study, we aimed to investigate whether the body fat distribution 
and cardiometabolic consequences of obesity had differential impact on risk of 
arterial and venous thrombosis. Calculating the risk of two outcomes within the same 
cohort would allow us to assess the influence of potentially shared risk factors.  
Therefore, we compared the impact of various obesity measures on the risk of MI 
and VTE in analyses with and without adjustment for atherosclerotic risk factors 
within a population-based cohort recruited from a general population.  
 
Material and Methods 
Study Population 
Participants were recruited from the fourth survey of the Tromsø Study, a single-
center, prospective, population-based health study, with repeated health surveys of 
inhabitants in Tromsø, Norway. The fourth survey was carried out in the period 
1994–1995 and consisted of two screening visits with an interval of 4–12 weeks. All 
women born in the period 1920–1944 and all men born in 1920–1939, and 5% to 
10% samples of subjects born 1940 to 1970, and 1910 to 1919, were invited to the 
more extensive second visit. A total of 7965 subjects attended, yielding a response 
rate of 77% in women and 74% in men. The study was approved by the regional 
committee for medical research ethics and all participants gave their informed written 
consent to participate. Among the subjects who attended, 1055 were women 
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participating in a sub-study with limited evaluation data; these were excluded from 
our study. Subjects who did not give written consent to participate in medical 
research (n=49), subjects with prior VTE (n=26), subjects with prior MI (n=401), 
subjects not officially registered as inhabitants of the municipality of Tromsø at the 
date of examination (n=7), and subjects for whom data of BMI, body height, WC or 
HC were not available (n=48) were excluded. Hence, a total of 6379 subjects were 
included in our study and followed from the date of enrolment in 1994-1995 up to the 
end of the study period, January 1, 2011.  
 
Measurements 
Baseline information was collected by physical examination, non-fasting blood 
samples, and self-administered questionnaires. Anthropometric measures were 
performed with subjects wearing short-sleeved garments and no shoes. Body mass 
index (BMI) was calculated as weight in kilograms divided by the square of height in 
meters (kg/m2). WC was measured in centimeters at the umbilical line. HC was 
measured in centimeters at the widest point at the hips. WHR ratios were calculated 
by dividing WC by HC. WHtR ratios were calculated by dividing WC by body height in 
centimeters. Information on self-reported diabetes and current smoking was collected 
from a self-administrated questionnaire. Blood pressure was recorded with an 
automatic device (Dinamap Vital Signs Monitor 1846, Critikon Inc.) by trained 
personnel. Participants rested for 2 minutes in a sitting position, and then 3 readings 
were taken on the upper right arm separated by 2-minute intervals. The average of 
the last 2 readings was used in the analysis. Nonfasting blood samples were 
collected from an antecubital vein, serum prepared by centrifugation after 1 hour 
respite at room temperature and analyzed at the Department of Clinical Chemistry, 
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University Hospital of North Norway. Serum total cholesterol and triglycerides were 
analyzed by enzymatic colorimetric methods and commercially available kits (CHOD-
PAP for cholesterol and GPO-PAP for triglycerides: Boeringer Mannheim, Germany). 
Serum HDL-cholesterol was measured after precipitation of lower-density 
lipoproteins with heparin and manganese chloride. Determination of glycosylated 
hemoglobin (HbA1c) in EDTA whole blood was based on an immunoturbidometric 
assay (UNIMATES, F. Hoffmann-La Roche AG). The HbA1c percent value was 
calculated from the HbA1c/Hb ratio. 
 
Outcome Assessment of Venous Thrombosis 
Only symptomatic (e.g. fatal or required treatment) VTE events were included. All 
first events of VTE were identified by searching the hospital discharge diagnosis 
registry, the autopsy registry, and the radiology procedure registry at the University 
Hospital of North Norway from date of enrolment in the Tromsø study (1994–1995) to 
January 1, 2011. All hospital care and relevant diagnostic radiology in the Tromsø 
municipality is provided exclusively by this hospital. The relevant discharge codes 
were ICD-9 codes 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9, for the period 
1994–98, and ICD-10 codes I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1, O87.3 for 
the period 1999–2007. The hospital discharge diagnosis register included diagnoses 
from outpatient clinic visits and hospitalizations. An additional search through the 
computerized index of autopsy diagnoses was conducted, and cases diagnosed with 
VTE, either as a cause of death (part one of the death certificate), or as a significant 
condition (part two of the death certificate), were identified. We also searched the 
radiology database to identify potential cases of objectively confirmed VTE that may 
have been missed because of coding errors in the index of medical diagnoses. All 
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relevant diagnostic procedures performed at the Department of Radiology, to 
diagnose VTE during the 13-year period, were systematically reviewed by trained 
personnel, and cases with objectively confirmed VTE were identified. 
The medical records for each potential VTE case, derived from the hospital 
discharge diagnosis register, the autopsy register, or the radiology procedure 
register, were reviewed by trained personnel (i.e. research staff with medical 
background who were specifically trained in registration of VTE). A panel consisting 
of senior medical researchers validated the records in cases where there was doubt 
to whether the inclusion criteria were met. The personnel who recorded the events 
were blinded to the baseline variables. For subjects derived from the hospital 
discharge diagnosis register and the radiology procedure register, an episode of VTE 
was verified and recorded as a validated outcome when all four of the following 
criteria were fulfilled: (i) objectively confirmed by diagnostic procedures (compression 
ultrasonography, venography, spiral-CT, perfusion-ventilation scan, pulmonary 
angiography or autopsy); (ii) the medical record indicated that a physician had made 
a diagnosis of DVT or PE; (iii) signs and symptoms consistent with DVT or PE were 
present; (iv) therapy with anticoagulants (heparin, warfarin, or a similar agent), 
thrombolytic agents or vascular surgery were required. For subjects derived from the 
autopsy registry, a VTE event was recorded as an outcome when the autopsy record 
indicated VTE as cause of death or as a significant condition. 
 
Outcome Assessment of Myocardial Infarction 
Adjudication of hospitalized and out-of hospital events was performed by an 
independent endpoint committee and based on data from hospital and out-of hospital 
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journals, autopsy records, and death certificates. The national 11-digit identification 
number allowed linkage to national and local diagnosis registries. Cases of incident 
myocardial infarction were identified by linkage to the discharge diagnosis registry at 
the University Hospital of North Norway (UNN) with search for ICD 9 codes 410-414 
in the period 1994-98 and thereafter ICD 10 codes I20-I25. The hospital medical 
records were retrieved for case validation. Modified WHO MONICA/MORGAM  (24) 
criteria for myocardial infarction were used and included clinical symptoms and signs, 
findings in electrocardiograms (ECG), values of cardiac biomarkers and autopsy 
reports when applicable. Further, linkage to the National Causes of Death Registry at 
Statistics Norway allowed identification of fatal incident cases of myocardial infarction 
that occurred as out-of-hospital deaths, including deaths that occurred outside of 
Tromsø, as well as information on all-cause mortality. Information from the death 
certificates was used to collect relevant information of the event from additional 
sources such as autopsy reports and records from nursing homes, ambulance 
services and general practitioners. 
 
Statistical Analyses 
Follow-up time and risk estimates were calculated separately for VTE and MI. For 
each participant, person-years of follow-up were accrued from the date of enrolment 
in the Tromsø Study through the date the event of interest (e.g. VTE or MI) was 
diagnosed, the date the participant died or officially moved from the municipality of 
Tromsø, or up to the end of the study period January 1, 2011. During the follow-up 
period, 527 persons moved from the municipality of Tromsø and 1756 persons died.  
Statistical analyses were carried out using Stata version 13 (Statacorp LP). 
For BMI (kg/m2), overweight was defined as BMI 25 to 29.9 kg/m2 and obesity as BMI 
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≥30 kg/m2 in both genders (25). For WC (cm), abdominal overweight was defined as 
≥80 cm in women and ≥94 cm in men, and abdominal obesity was defined as ≥88 cm 
in women and ≥102 cm in men (25, 26). For WHR (ratio), obesity was defined as 
≥0.85 in women and ≥0.95 in men (27). Gender specific Cox-proportional hazards 
regression models were used to estimate hazard ratios (HR) with 95% confidence 
intervals (CI) for VTE and MI per 1 standard deviation (SD) increase in the 
anthropometric measurements, and to assess the risk of VTE and MI associated with 
established definitions of obesity. Analyses were performed in two adjustments 
models. Model 1 included age and smoking, whereas model 2 additionally included 
systolic blood pressure, total cholesterol, HDL cholesterol, triglycerides, HbA1C and 
self-reported diabetes mellitus In addition, Cox-proportional hazard regression 
models were used to calculate gender specific HR across quintiles (supplementary 
table 1) of the different anthropometric measures. The proportional hazard 
assumption was verified by evaluating the parallelism between the curves of the log-
log survivor function for different categories of the variables. Figures were created 
and processed in Graphpad Prism 5 (Graphpad Software Inc.) and Adobe Creative 
Suite 6 (Adobe Systems Software Ireland Ltd.). Adobe Systems Software Ireland Ltd 
 
Results 
The mean baseline age was 61 years (range=25-84, SD=10.2) and 47.7% (n=3043) 
were men. There were 925 incident MIs and 288 incident VTEs during a median 
follow-up of 15.7 years. Thirty-eight subjects developed both MI and VTE during 
follow-up. The overall crude incidence rates were 11.3 (95% CI: 10.6–12.1) per 1000 
person-years for MI, and 3.4 (95% CI: 3.0–3.8) per 1000 person-years for VTE.  
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Table 1 shows the distribution of traditional atherosclerotic risk factors and 
anthropometric measures in men and women. Subjects with incident VTE during 
follow-up had higher BMI, WC, HC, WHR and WHtR than subjects with incident MI, 
whereas subjects with no event during follow-up had the lowest values. Baseline 
levels of traditional cardiovascular risk factors were higher among subjects with 
incident MI. 
Hazard ratios for VTE and MI per 1 SD increase in the anthropometric 
measures are shown in table 2. In analyses adjusted for age and smoking, all 
anthropometric measures were significantly associated with risk of VTE, with risk 
estimates ranging from 19 to 38% increased risk per 1SD. Similar results were found 
for risk of MI, except for hip circumference which showed a weaker association. WC 
exhibited the highest risk estimate for VTE in both genders (age-adjusted HR 1.28 
(95% CI: 1.15-1.54) in women and 1.38 (95% CI: 1.17-1.63) in men), whereas WHtR 
exhibited the highest risk estimate for MI (age-adjusted HR 1.28 (95% CI: 1.16-1.42) 
for women and 1.29 (95% CI: 1.19-1.40) for men). The risk estimates for MI were 
markedly lowered (9-19 percentage points) after adjustment for traditional 
cardiovascular risk factors, whereas the risk estimates for VTE remained unchanged 
or were slightly increased (Table 2). 
Analyses evaluating risks according to established criteria for obesity are 
shown in table 3. In men, 11%, 21% and 27% were obese according to the WHO cut-
offs for BMI, WC and WHR, respectively. In women, the corresponding figures were 
17%, 37% and 29%. Obesity, determined by established criteria, remained 
associated with VTE risk even after adjustment for atherosclerotic risk factors.  BMI, 
WC and WHR cut-off levels were associated with increased risk of VTE in women, 
while only BMI and WC was associated VTE risk in men. In contrast, no associations 
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were found between BMI or WC and future risk of MI after adjustment for 
atherosclerotic risk factors. WHR, however, was associated with a 26% higher risk of 
MI in men even after adjustment (Table 3).  
In quintile-based analyses (Figure 1), the risk of VTE increased across higher 
quintiles of all obesity measures in both genders, and remained unchanged after 
adjustment for systolic blood pressure, total cholesterol, HDL cholesterol, 
triglycerides, HbA1C and diabetes mellitus. In women, hip circumference yielded the 
highest risk estimates for VTE, with adjusted HR of 2.27 (95% CI: 1.54-4.92). BMI, 
WC and WHR were associated with risk of MI, but the risk estimates were 
attenuated, and for BMI and WC no longer statistically significant, after adjustments 
for atherosclerotic risk factors. In men, waist circumference yielded the highest risk 
estimates (HR upper vs. bottom quintile: 3.54, 95% CI 1.82-7.06).  Apparently, there 
was a threshold effect between the first and second quintile, with adjusted HR of 2.46 
for the second quintile compared to the first. All anthropometric measures were 
associated with increased risk of MI in men, but hip circumference showed a weaker 
association than the other measures. The risk estimates for MI were substantially 
lowered (33-68 percentage points) after adjustment for atherosclerotic risk factors, 
while the risk estimates for VTE remained unchanged or were slightly increased. 
WHtR yielded similar HRs compared to WHR in both genders (data not shown). 
 
Discussion 
In the present study, obese individuals with high HC, a measure of 
subcutaneous fat (28), were at high risk of VTE, while a much weaker association 
was found between HC and risk of MI. In women, a high HC showed a protective 
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effect against MI after multivariable adjustments, though the results were not 
statistically significant. Measures of abdominal obesity, which reflect visceral fat (28), 
were associated with high risk estimates for both MI and VTE. All risk estimates for 
MI were substantially reduced after adjustment for traditional atherosclerotic risk 
factors, whereas the risk estimates for VTE remained unchanged. Our findings 
suggest that body fat distribution is more important for risk of MI than VTE in obese 
subjects, and likewise, that the metabolic disturbances associated with obesity (18) 
show a different degree of association with the two disease entities.  
In accordance with our findings, Glynn and co-workers showed that obesity, 
assessed by BMI, was a stronger predictor for VTE than for coronary heart disease in 
a cohort of male physicians (8). However, as they did not investigate other 
anthropometric measures or adjust for covariates, our study is the first to directly 
compare the impact of these factors on the two outcomes.   
Our findings of visceral obesity as an important predictor of MI are in 
agreement with previous findings in observational studies. In the INTERHEART 
study, a case-control study of 27 000 participants from 52 countries, WHR was the 
strongest predictor of MI, and subjects in the upper quintile had a 2.5 fold higher risk 
than those in the lower quintile (12). The discriminatory power of WHR on risk of MI 
has been confirmed in two meta-analyses (13, 20), and several large studies, 
including the INTERHEART study, have reported lower risk of MI with increasing HC 
(12, 29, 30). Cardiometabolic abnormalities associated with obesity are dependent 
on body fat distribution and accumulation of visceral adipose tissue, and 
experimental evidence supports a causal relation (18, 31-33). In large cross-sectional 
studies, visceral fat, assessed by CT, was unfavourably associated with insulin 
resistance, serum lipid levels and blood pressure (34-36). In contrast, subcutaneous 
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adipose tissue, and the gluteofemoral fat depot in particular, exhibited a protective 
role against an unfavourable metabolic profile (37-40).  It has been suggested that 
gluteofemoral adipose tissue acts as a “metabolic sink”, by trapping excess fatty 
acids from the circulation (18). Similar to our findings, previous cohort and case-
control studies have shown that risk estimates for MI by anthropometric obesity 
measures were substantially lowered after adjustment for traditional atherosclerotic 
risk factors (12, 41, 42), supporting the concept that these risk factors partially 
mediates the risk of MI in obesity assuming that they were not present before 
obesity. 
Few previous studies have investigated the impact of obesity measures on 
VTE risk. The Danish Diet, Cancer and Health Study followed 57 054 individuals for a 
median of 10 years, and reported that all anthropometric measures of obesity were 
associated with higher risk of VTE, with WC as the strongest predictor among men, 
and HC and BMI as the strongest among women (16). In the Iowa Women`s Health 
Study (43) of 40377 women aged ≥65, all anthropometric measures were associated 
with increased risk of VTE. Furthermore, both WC and HC (highest versus lowest 
tertile) were associated with more than 50% higher risk of VTE after adjustment for 
BMI, which indicates that both WC and HC are important for risk assessment of VTE 
in women (43). However, this may partly be due to the fact that peripheral and central 
obesity often coexist, as hip circumference is correlated with visceral fat (44). In the 
Copenhagen City Heart Study (11), BMI and WHR were associated with increased 
risk of VTE in women, while WHR was only modestly associated with VTE in men. 
The majority of cohort studies found no association between traditional 
cardiovascular risk factors and risk of VTE (6-11).  Hence, it is not surprising that the 
association between obesity measures and risk of VTE was unaffected by 
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adjustment for cardiovascular risk factors. Moreover, abdominal obesity was 
mandatory for the apparent association between the metabolic syndrome and risk of 
VTE, whereas none of the other components of the syndrome, alone or in cluster, 
were associated with VTE (10, 17, 45). Thus, our findings further support the notion 
that the increased risk of VTE in obese subjects is not dependent of the 
cardiometabolic consequences of obesity, and that targeted reduction of 
atherosclerotic risk factors presumably will not be useful in preventing obesity-related 
VTE. 
The underlying mechanism(s) for the strong associations between obesity 
measures and risk of VTE are not fully understood. The endocrine and paracrine 
function of adipose tissue has gained interest in the recent years. Obesity is 
associated with a state of chronic low-grade inflammation (46). However, although 
studies have indicated an association between inflammation and coagulation (47), 
the role of inflammatory markers in the risk of VTE is unclear (48-50). Obesity is 
associated with increased levels of procoagulant and hypofibrinolytic agents such as 
coagulation factor VIII, fibrinogen and plasminogen activator inhibitor 1, which may 
increase VTE risk (51). However, in a study of postmenopausal women, there was an 
inverse association between HC and coagulation activity after adjustment for WC 
(52), which is in contrast to the strong association between HC and VTE.  
Adipokines, such as adiponectin, leptin and resistin, are physiologically active 
proteins secreted by adipose tissue that are involved in metabolic processes. In a 
small case-control study, leptin and resistin were associated with increased risk of 
chronic venous disease (53). To our knowledge, no study has investigated the impact 
of adipokines on VTE risk. Obesity-induced stasis is another potential mechanism for 
the increased VTE risk, either alone or in combination with inflammation. Stasis is a 
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well-recognized risk factor for VTE, and Willenberg et al. showed that abdominal 
obesity was accompanied by venous stasis caused by increased intra-abdominal 
pressure (54, 55), and in a small study of 10 morbidly obese subjects, weight loss 
due to laparoscopic sleeve gastrectomy significantly improved blood flow of the 
femoral veins (56). 
The main strengths of our study are the prospective design, long-term follow-
up, large number of participants, and validated VTE and MI-events. All hospital-care 
in the region is exclusively provided by a single hospital, which facilitates the 
completeness of our outcome registries. Some limitations merit consideration. The 
out-of-hospital events may be more prone to misclassification due to less informative 
medical records. In addition, there is always a potential for unrecognized fatal events. 
Nondifferential misclassification, which leads to bias toward the null, is often pointed 
out as a potential limitation of cohort studies when exposure is self-reported or 
modifiable over time. When comparing the impact of body fat distribution on risk of MI 
and VTE within the same population, the degree of random misclassification of 
exposure and co-variates would be similar with regard to both outcomes. Even 
though our study design ensures equal distribution of unrecognized confounders, 
these may have differential impact on the outcomes.  As body weight tend to 
increase with age (57), this probably leads to underestimation of associations for the 
anthropometric measures. Lastly, there will potentially be some degree of 
unmeasured confounding, such as the use of lipid lowering and antihypertensive 
drugs. 
In conclusion, our findings suggest that the impact of body fat distribution, and 
the causal pathway, differs for the association between obesity and arterial and 
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venous thrombosis. Further studies are warranted to shed light over the mechanisms 
for risk of VTE in obesity in order to tailor preventive actions in the future. 
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Figure 1. Gender-Specific Hazard Ratios With 95% Confidence Intervals for 
Venous Thromboembolism (VTE) and Myocardial Infarction (MI) Across 
Quintiles of Anthropometric Measures. The Tromsø Study (1994-2011). The 
lowest quintile is used as reference. Intervals are shown in supplementary table 1. 
BMI indicates body mass index; WC, waist circumference; HC, hip circumference; 
WHR, waist-hip ratio. A, Women, adjusted for age and smoking. B, Women, adjusted 
for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, 
triglycerides, HbA1C and self-reported diabetes mellitus. C, Men, adjusted for age 
and smoking. D, Men, adjusted for age, smoking, systolic blood pressure, total 
cholesterol, HDL cholesterol, triglycerides, HbA1C and self-reported diabetes 
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Table 1. Baseline Characteristics of Subjects With Incident VTE (VTE), Incident Myocardial Infarction 
(MI) and With No Event During Follow-Up. The Tromsø Study (1994-2011). Values are means  ± 1 SD 
or percentage with numbers in brackets 
  Women (n=3336)  Men (N=3043) 
         
Variables  VTE  MI  No Event  VTE MI No Event 
    (n=158) (n=362) (n=2833)    (n=130) (n=563) (n=2371) 
Age, y  64.4 ± 7.3 66.2  ± 6.3 59.6  ± 10.5  63.1 ± 6.8 63.1 ± 7.8 58.2 ± 10.5 
BW, kg  71.6 ± 11.2 68.6 ± 13.4 67.4  ± 11.6  83.0 ± 12.0 80.6 ± 12.4 79.7 ± 12.0 
Height, cm  161.8 ± 6.3 159.6 ± 5.9 161.8  ± 6.3  176.3 ± 6.3 174.3 ± 6.7 175.4  ± 6.9 
BMI, kg/m2 27.4 ± 4.2 26.9 ± 5.1 25.8  ± 4.3  26.7 ± 3.3 26.5 ± 3.5 25.9 ± 3.3 
WC, cm  89.1 ± 10.5 88.2 ± 12.2 84.4  ± 10.8  98.0 ± 8.8 96.8 ± 9.6 94.2 ± 9.2 
HC, cm  106.2 ± 8.4 104.6 ± 10.1 103.1  ± 9.0  104.8 ± 6.1 103.6 ± 6.5 103.1 ± 6.1 
WHR, ratio 0.84 ± 0.07 0.84  ± 0.06 0.82  ± 0.07  0.93 ± 0.06 0.93 ± 0.07 0.91 ± 0.06 
WHtR, ratio 0.55 ± 0.07 0.55  ±  0.08 0.52  ± 0.07  0.56 ± 0.05 0.56 ± 0.05 0.54 ± 0.05 
Smoking  27.2 (43) 39.1 (141) 30.3 (858)  32.6 (43) 38.9 (219) 34.9 (827) 
SBP, mm Hg 150.0 ± 23.8 158.8 ± 24.3 143.1  ± 23.8  148.9 ± 19.9 151.0 ± 21.2 143.5 ± 19.8 
DBP, mm Hg 83.3 ± 12.9 87.1  ± 14.4 81.0  ± 13.1  87.0 ± 12.0 87.7 ± 12.5 84.4 ± 12.1 
Total-C, mmol/L 7.28 ± 1.30 7.31  ± 1.28 6.85  ± 1.34  6.54 ± 0.96 6.78 ± 1.18 6.47 ± 1.22 
HDL-C, mmol/L 1.65 ± 0.42 1.62  ± 0.44 1.69  ± 0.43  1.43 ± 0.36 1.34 ± 0.37 1.41 ± 0.40 
TAG, mmol/L 1.73 ± 0.95 1.81  ± 1.04 1.52  ± 0.90  1.68 ± 0.94 1.94 ± 1.11 1.78 ± 1.17 
HbA1c, %  5.6 ± 0.9 5.7  ± 0.9 5.4  ± 0.6  5.5 ± 0.5 5.6 ± 0.8 5.4 ± 0.6 
DM   3.2 (5) 8.9 (32) 2.2 (63)   5.0 (7) 6.1 (34) 2.1 (49) 
BW indicates body weight; BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, 
waist-hip ratio; WHtR, Waist-height ratio, SBP, systolic blood pressure; DBP, diastolic blood pressure; Total-C, 







Table 2. Gender-Specific Hazard Ratios (HR) of Venous Thromboembolism (VTE) and Myocardial Infarction (MI) With 95% Confidence 
Intervals (95% CI) per 1 SD Increase in the Anthropometric Measures. The Tromsø Study (1994-2011) 
 VTE  MI 
    Model 1*  Model 2†  Model 1* Model 2† 
    Mean SD (95% CI) (95% CI)   (95% CI) (95% CI) 
Women (n=3336)        
 BMI, kg/m
2 26.0 4.5 1.26 (1.09-1.46) 1.30 (1.09-1.55)  1.20 (1.09-1.33) 1.02 (0.91-1.16) 
 WC, cm 85 11.1 1.33 (1.15-1.54) 1.43 (1.20-1.71)  1.23 (1.11-1.36) 1.04 (0.92-1.18) 
 HC, cm 103.4 9.1 1.28 (1.10-1.48) 1.32 (1.11-1.57)  1.11 (1.00-1.24) 0.96 (0.86-1.09) 
 WHR 0.82 0.07 1.19 (1.04-1.36) 1.21 (1.06-1.40)  1.18 (1.08-1.29) 1.09 (0.98-1.21) 
 WHtR 0.53 0.07 1.27 (1.09-1.48) 1.35 (1.12-1.62)  1.28 (1.16-1.42) 1.09 (0.96-1.23) 
Men (n=3043)        
 BMI, kg/m
2 26.0 3.4 1.25 (1.05-1.48) 1.30 (1.07-1.58)  1.23 (1.13-1.33) 1.06 (0.97-1.17) 
 WC, cm 94.8 9.3 1.38 (1.17-1.63) 1.47 (1.22-1.78)  1.25 (1.15-1.35) 1.09 (1.00-1.20) 
 HC, cm 103.2 6.2 1.32 (1.11-1.57) 1.31 (1.07-1.59)  1.11 (1.02-1.21) 0.99 (0.91-1.09) 
 WHR 0.92 0.06 1.26 (1.09-1.47) 1.35 (1.15-1.59)  1.26 (1.17-1.35) 1.13 (1.04-1.23) 
  WHtR 0.54 0.05 1.26 (1.06-1.49) 1.36 (1.12-1.65)   1.29 (1.19-1.40) 1.13 (1.02-1.24) 
* Adjusted for age and smoking 













Table 3. Gender-Specific Hazard Ratios (HR) of Venous Thromboembolism (VTE) and Myocardial Infarction (MI) With 95% Confidence Intervals (95% CI) 
by Established Criteria for Obesity. The Tromsø Study (1994-2011) 
  VTE  MI 
 n (%) IR* HR Model 1†  HR Model 2‡  IR* HR Model 1† HR Model 2‡ 
Women (n=3336)         
    BMI, kg/m2         
       <25 1526 (45.7) 2.2 (1.7-3.0) Ref Ref  6.9 (5.8-8.1) Ref Ref 
       25-29.9 1240 (37.2) 4.0 (3.2-5.1) 1.55 (1.06-2.27) 1.42 (0.94-2.15)  8.1 (6.8-9.6) 1.04 (0.82-1.33) 0.96 (0.74-1.25) 
       ≥30 570 (17.1) 5.6 (4.2-7.6) 2.14 (1.40-3.28) 2.14 (1.33-3.45)  11.7 (9.2-14.4) 1.48 (1.13-1.95) 1.00 (0.73-1.37) 
       P for trend   0.000 0.002   0.011 0.961 
    WC, cm         
       <80 1125 (33.7) 1.8 (1.3-2.6) Ref Ref  6.1 (5.0-7.5) Ref Ref 
       80-87.9 990 (29.7) 2.7 (1.9-3.7) 1.29 (0.78-2.11) 1.49 (0.86-2.58)  7.3 (6.0-8.9) 1.04 (0.78-1.39) 0.93 (0.69-1.26) 
       ≥88 1221 (36.6) 5.7 (4.7-7.0) 2.53 (1.64-3.90) 3.15 (1.90-5.22)  10.7 (9.2-12.5) 1.33 (1.03-1.72) 0.98 (0.73-1.31) 
       P for trend   0.000 0.000   0.022 0.930 
    WHR            
       <0.85 2382 (71.4) 2.9 (2.3-3.5) Ref Ref  6.9 (6.0-7.8) Ref Ref 
       ≥0.85 954 (28.6) 5.1 (4.0-6.5) 1.50 (1.09-2.08) 1.64 (1.15-2.35)  11.5 (9.8-13.6) 1.31 (1.06-1.62) 1.06 (0.84-1.34) 
       P for trend   0.013 0.006   0.014 0.643 
Men (n=3043)         
    BMI, kg/m2         
       <25 1203 (39.5) 2.6 (1.9-3.6) Ref Ref  12.9 (11.1-14.8) Ref Ref 
       25-29.9 1507 (49.5) 3.7 (2.9-4.7) 1.47 (0.99-2.17) 1.38 (0.90-2.13)  18.6 (14.2-18.0) 1.37 (1.13-1.64) 1.12 (0.92-1.37) 
       ≥30 333 (10.9) 4.0 (2.5-6.5) 1.66 (0.86-3.18) 1.65 (0.88-3.10)  20.0 (16.0-25.0) 1.77 (1.35-2.31) 1.13 (0.85-1.57) 
       P for trend   0.037 0.082   0.000 0.259 
    WC, cm         
       <94 1420 (46.7) 2.5 (1.8-3.3) Ref Ref  11.8 (10.3-13.5) Ref Ref 
       94-101.9 978 (32.1) 3.4 (2.5-4.6) 1.33 (0.87-2.02) 1.34 (0.84-2.12)  16.7 (14.5-19.2) 1.40 (1.15-1.70) 1.11 (0.90-1.37) 
       ≥102 645 (21.2) 5.3 (3.9-7.1) 1.95 (1.28-2.99) 2.20 (1.36-3.57)  20.5 (17.5-24.0) 1.63 (1.32-2.02) 1.21 (0.96-1.53) 
       P for trend   0.002 0.002   0.000 0.103 
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    WHR            
       <0.95 2220 (73.0) 3.0 (2.4-3.6) Ref Ref  12.9 (11.6-14.3) Ref Ref 
       ≥0.95 823 (27.0) 4.4 (3.3-5.9) 1.36 (0.94-1.95) 1.62 (1.08-2.42)  21.7 (18.9-24.9) 1.50 (1.26-1.78) 1.26 (1.04-1.52) 
       P for trend     0.103 0.019     0.000 0.018 
*Crude incidence rate per 1000 person years with 95% confidence intervals    
†Adjusted for age and smoking  
 ‡ Adjusted for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, triglycerides, HbA1C and self-reported diabetes mellitus 
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